Clinical Trials Directory

Trials / Completed

CompletedNCT04922476

Effect of 35624® Alflorex® in Functional Gastrointestinal Disorders (FGIDs) in Children.

Open Label Clinical Trial on the Efficacy of a Probiotic Strain of Bifidobacterium Longum 35624 (Alflorex®) in Functional Gastrointestinal Disorders (GFRS) in Children 8 to 18 Years of Age.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
65 (actual)
Sponsor
PrecisionBiotics Group Ltd. · Industry
Sex
All
Age
8 Years – 18 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to evaluate the effect of supplementation with Bifidobacterium longum 35624® Alflorex® on frequency and severity of symptoms of abdominal pain using an adapted Irritable Bowel Symptom Severity Scoring System (IBS-SSS) to accurately reflect the pediatric population using the aid of the validated Numeric Pain Rating Scale (NRS-II) in children with Functional Gastrointestinal Disorders (FGIDs).

Detailed description

This is an open label study to assess the safety and effectiveness of Bifidobacterium longum 35624® Alflorex® when consumed once daily by children with Functional Gastrointestinal Disorders (FGIDs). The 12-week intervention study will be conducted in 63 non-coeliac children aged 8 to 18 years old with an FGID who experience at least two episodes of abdominal pain per week. The study will consist of 5 visits over a 14 week period commencing with a screening visit. The second visit will be the baseline (start of intervention), followed by third (mid-intervention), fourth (end of treatment) and fifth (follow up) visit. Questionnaires will be administered from the second to the fifth visit. A blood sample will be taken before treatment to rule out coeliac disease.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTAlflorex®Each probiotic capsule contains 1 x 10\^9 CFU of B. longum 35624® and corn starch, hydroxypropyl methyl cellulose and magnesium stearate.

Timeline

Start date
2021-08-06
Primary completion
2023-03-04
Completion
2023-04-04
First posted
2021-06-10
Last updated
2023-09-08

Locations

1 site across 1 country: Chile

Source: ClinicalTrials.gov record NCT04922476. Inclusion in this directory is not an endorsement.